Last Updated: November 16, 2026

Investigational Drug Information for JNJ-70033093

« Back to Dashboard


What is the development status for investigational drug JNJ-70033093?

JNJ-70033093 is an investigational drug.

There have been 12 clinical trials for JNJ-70033093. The most recent clinical trial was a Phase 2 trial, which was initiated on March 8th 2023.

The most common disease conditions in clinical trials are Ischemia, Cerebral Infarction, and Syndrome. The leading clinical trial sponsors are Janssen Research & Development, LLC, Bristol-Myers Squibb, and Janssen Pharmaceutica N.V., Belgium.

There are eleven US patents protecting this investigational drug and one hundred and twenty-six international patents.

Recent Clinical Trials for JNJ-70033093
TitleSponsorPhase
A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeJanssen Research & Development, LLCPhase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic AttackBristol Myers Squibb Company (BMS)Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic AttackJanssen Research & Development, LLCPhase 3

See all JNJ-70033093 clinical trials

Clinical Trial Summary for JNJ-70033093

Top disease conditions for JNJ-70033093
Top clinical trial sponsors for JNJ-70033093

See all JNJ-70033093 clinical trials

US Patents for JNJ-70033093

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
JNJ-70033093 ⤷  Start Trial Pyrimidinones as factor XIa inhibitors Bristol Myers Squibb Co ⤷  Start Trial
JNJ-70033093 ⤷  Start Trial Pyrimidinones as factor XIA inhibitors Bristol Myers Squibb Co ⤷  Start Trial
JNJ-70033093 ⤷  Start Trial Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane Boulder Bioscience LLC ⤷  Start Trial
JNJ-70033093 ⤷  Start Trial Substituted S-alaninate derivatives Bayer AG ⤷  Start Trial
JNJ-70033093 ⤷  Start Trial Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane Boulder Bioscience LLC ⤷  Start Trial
JNJ-70033093 ⤷  Start Trial Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof Bristol Myers Squibb Co ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for JNJ-70033093

Drugname Country Document Number Estimated Expiration Related US Patent
JNJ-70033093 Argentina AR099227 2034-01-31 ⤷  Start Trial
JNJ-70033093 Argentina AR099550 2034-01-31 ⤷  Start Trial
JNJ-70033093 Argentina AR101367 2034-01-31 ⤷  Start Trial
JNJ-70033093 Australia AU2015210904 2034-01-31 ⤷  Start Trial
JNJ-70033093 Australia AU2015324530 2034-01-31 ⤷  Start Trial
JNJ-70033093 Australia AU2019216617 2034-01-31 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.